tert-butyl 4-(3,5-bis(trifluoromethyl)phenyl)piperazine-1-carboxylate | 1121599-75-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 4-(3,5-bis(trifluoromethyl)phenyl)piperazine-1-carboxylate
• 英文别名: 1,1-Dimethylethyl 4-[3,5-bis(trifluoromethyl)phenyl]-1-piperazinecarboxylate；tert-butyl 4-[3,5-bis(trifluoromethyl)phenyl]piperazine-1-carboxylate
• CAS: 1121599-75-4
• 化学式: C₁₇H₂₀F₆N₂O₂
• 分子量: 398.348
• InChiKey: GKQHYNKTRGXCGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.78
• 重原子数：
  27.0
• 可旋转键数：
  1.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  32.78
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(3,5-bis(trifluoromethyl)phenyl)piperazine-1-carboxylate 在 caesium carbonate 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 5.0h， 生成
  参考文献：
  名称：

  CN116621794

  摘要：

  公开号：
• 作为产物：
  描述：

  N-Boc-哌嗪 、 alkaline earth salt of/the/ methylsulfuric acid 在 palladium diacetate 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 甲苯 为溶剂， 生成 tert-butyl 4-(3,5-bis(trifluoromethyl)phenyl)piperazine-1-carboxylate
  参考文献：
  名称：

  4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide (ML267), a Potent Inhibitor of Bacterial Phosphopantetheinyl Transferase That Attenuates Secondary Metabolism and Thwarts Bacterial Growth

  摘要：

  4'-Phosphopantetheinyl transferases (PPTases) catalyze a post-translational modification essential to bacterial cell viability and virulence. We present the discovery and medicinal chemistry optimization of 2-pyridinyl-N-(4-aryl)-piperazine-1-carbothioamides, which exhibit submicromolar inhibition of bacterial Sfp-PPTase with no activity toward the human orthologue. Moreover, compounds within this class possess antibacterial activity in the absence of a rapid cytotoxic response in human cells. An advanced analogue of this series, ML267 (55), was found to attenuate production of an Sfp-PPTase-dependent metabolite when applied to Bacillus subtilis at sublethal doses. Additional testing revealed antibacterial activity against methicillin-resistant Staphylococcus aureus, and chemical genetic studies implicated efflux as a mechanism for resistance in Escherichia coli. Additionally, we highlight the in vitro absorption, distribution, metabolism; and excretion and in vivo pharmacokinetic profiles of compound 55 to further demonstrate the potential utility of this small-molecule inhibitor.

  DOI：

  10.1021/jm401752p

文献信息

• Multitargeted Compounds Derived from (2,5-Dioxopyrrolidin-1-yl)(phenyl)-Acetamides as Candidates for Effective Anticonvulsant and Antinociceptive Agents
  作者：Michał Abram、Anna Rapacz、Szczepan Mogilski、Gniewomir Latacz、Annamaria Lubelska、Rafał M. Kamiński、Krzysztof Kamiński

  DOI：10.1021/acschemneuro.0c00257

  日期：2020.7.1

  pyrrolidine-2,5-dione derivatives with potent anticonvulsant and antinociceptive properties. These hybrid compounds demonstrated broad-spectrum protective activity in a range of mouse models, such as the maximal electroshock (MES) test, the pentylenetetrazole-induced seizures (scPTZ), and the 6 Hz (32 mA) seizures. Compound 22 showed the most potent anticonvulsant activity (ED50 MES = 23.7 mg/kg, ED50 6

  我们开发了一组重点集中的原始杂种吡咯烷-2,5-二酮衍生物，具有强大的抗惊厥和抗伤害感受特性。这些杂合化合物在一系列小鼠模型中表现出广谱的保护活性，例如最大电击（MES）测试，戊烯四唑诱导的癫痫发作（sc PTZ）和6 Hz（32 mA）癫痫发作。化合物22显示出最有效的抗惊厥活性（ED 50 MES = 23.7 mg / kg，ED 50 6 Hz（32 mA）= 22.4 mg / kg，ED 50 sc PTZ = 59.4 mg / kg）。此外，有22种药物在福尔马林引起的强直性疼痛中显示出强效功效。这些体内活性的22可能是由几个靶标介导的，并且可能是由于抑制中央钠/钙电流和瞬时受体电位香草酸1（TRPV1）受体拮抗作用所致。最后，先导化合物22在体外测定中显示出类药物的吸收，分布，代谢，排泄，毒性（ADME-Tox）特性，使其成为癫痫和神经性疼痛指征进一步发展的潜在候选者。
• [EN] LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME<br/>[FR] COMPOSÉS DE CIBLAGE LPXH, LEURS COMPOSITIONS ET PROCÉDÉS DE FABRICATION ET D'UTILISATION ASSOCIÉS
  申请人：UNIV DUKE

  公开号：WO2021072369A1

  公开（公告）日：2021-04-15

  LpxH targeting compounds, compositions thereof, as well as methods for for making and using the same are disclosed herein. The LpxH target compounds typically have a structure pursuant to Formula (I) and/or a salt thereof, wherein Rb is selected from a single bond, C4 to C10 unsubstituted aryl, C4 to C10 substituted aryl, unsubstituted or substituted four to ten member heterocycle ring, C1 to C10 unsubstituted alkyl, and C1 to C10 substituted alkyl; Rc comprises hydrogen, halogen, -OH, -CO2CH3, -COOH, -CN2CF3, -CF3,-C2OH, -CONHOH, -CCOH, C4 to C10 unsubstituted aryl, C4 to C10 substituted aryl, unsubstituted or substituted four to ten member heterocycle ring, C1 to C10 unsubstituted alkyl, or C1 to C10 substituted alkyl; and Rd and Re are independently hydrogen, -OH, -COH, -COH, -COC, -COOH, Rf, or are taken together as an unsubstituted or substituted four to eight member nitrogen containing heterocycle ring.

  LpxH靶向化合物，其组合物，以及制备和使用这些化合物的方法在此披露。LpxH靶向化合物通常具有符合式(I)的结构和/或其盐，其中Rb从单键，C4到C10未取代芳基，C4到C10取代芳基，未取代或取代的四到十元杂环环，C1到C10未取代烷基，和C1到C10取代烷基中选择；Rc包括氢，卤素，-OH，-CO2CH3，-COOH，-CN2 ，-CF3，-C2OH，-CONHOH，-CCOH，C4到C10未取代芳基，C4到C10取代芳基，未取代或取代的四到十元杂环环，C1到C10未取代烷基，或C1到C10取代烷基；而Rd和Re独立地是氢，-OH，-COH，-COH，-COC，-COOH，Rf，或作为未取代或取代的四到八元含氮杂环环一起取代。
• Synthesis and evaluation of sulfonyl piperazine LpxH inhibitors
  作者：Seung-Hwa Kwak、C. Skyler Cochrane、Amanda F. Ennis、Won Young Lim、Caroline G. Webster、Jae Cho、Benjamin A. Fenton、Pei Zhou、Jiyong Hong

  DOI：10.1016/j.bioorg.2020.104055

  日期：2020.9

  of Klebsiella pneumoniae LpxH in complex with 1 (AZ1), a sulfonyl piperazine LpxH inhibitor. The analysis of the LpxH-AZ1 co-crystal structure and ligand dynamics led to the design of 2 (JH-LPH-28) and 3 (JH-LPH-33) with enhanced LpxH inhibition. In order to harness our recent findings, we prepared and evaluated a series of sulfonyl piperazine analogs with modifications in the phenyl and N-acetyl groups

  UDP-2,3-二酰基葡萄糖胺焦磷酸水解酶 LpxH 在脂质 A 生物合成中必不可少，并且已成为开发针对多重耐药革兰氏阴性病原体的新型抗生素的有希望的目标。最近，我们报道了与磺酰哌嗪 LpxH 抑制剂1 ( AZ1) 复合的肺炎克雷伯菌LpxH的晶体结构。LpxH-AZ1 共晶结构和配体动力学的分析导致设计了具有增强的 LpxH 抑制的2 (JH-LPH-28) 和3 (JH-LPH-33)。为了利用我们最近的发现，我们制备并评估了一系列磺酰基哌嗪类似物，它们的苯基和N-乙酰基修饰了3. 在此，我们描述了磺酰哌嗪 LpxH 抑制剂的合成和构效关系。我们还报告了与肺炎克雷伯菌LpxH复合的扩展N-酰基链类似物27b (JH-LPH-41)的结构分析，揭示了27b到达了K的活性位点中二锰簇附近未开发的极袋. 肺炎LpxH。我们希望我们的发现将为新的 LpxH 抑制剂提供设计原则，并为未来针对多
• New Phenylglycinamide Derivatives with Hybrid Structure as Candidates for New Broad-Spectrum Anticonvulsants
  作者：Marcin Jakubiec、Michał Abram、Mirosław Zagaja、Marta Andres-Mach、Aleksandra Szewczyk、Gniewomir Latacz、Bartłomiej Szulczyk、Katarzyna Socała、Dorota Nieoczym、Piotr Wlaź、Cameron S. Metcalf、Karen Wilcox、Rafał M. Kamiński、Krzysztof Kamiński

  DOI：10.3390/cells11121862

  日期：——

  In the present study, a focused combinatorial chemistry approach was applied to merge structural fragments of well-known TRPV1 antagonists with a potent anticonvulsant lead compound, KA-104, that was previously discovered by our group. Consequently, a series of 22 original compounds has been designed, synthesized, and characterized in the in vivo and in vitro assays. The obtained compounds showed robust

  在本研究中，应用集中的组合化学方法将众所周知的 TRPV1 拮抗剂的结构片段与我们小组先前发现的强效抗惊厥先导化合物KA-104合并。因此，在体内和体外试验中设计、合成和表征了一系列 22 种原始化合物。获得的化合物在最大电击 (MES) 测试和 6 Hz 癫痫模型（使用 32 和 44 mA 电流强度）中显示出强大的体内抗癫痫活性。最有效的化合物53和60显示出以下药理学特征：ED 50 = 89.7 mg/kg (MES)、ED 50 = 29.9 mg/kg (6 Hz, 32 mA)、ED 50= 68.0 mg/kg (6 Hz, 44 mA), ED 50 = 73.6 mg/kg (MES), ED 50 = 24.6 mg/kg (6 Hz, 32 mA), ED 50 = 56.3 mg/kg (6赫兹，44毫安），分别。此外，53和60对iv PTZ 癫痫发作阈值有效，